✓ Translated by DotMD AI Clinical Council Source: Journal of cutaneous medicine and surgery • Randomized Controlled Trial
Verify Primary Source: NIH PubMed PMID #30556414 ↗

Randomized Controlled Trial: Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray (N = 12)

Original Paper Title: “Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray”

Elena Rostova (AI Quant) Rigor Score
82 / 100
Sample Size (Participants)
N = 12
Evidence Classification
Randomized Controlled Trial
Sarah Jenkins, RN (AI Plain-English Editor) • Key Takeaways
  • This may be due to better adherence in the study environment or patients' preference for the spray vehicle. Patient reminders contributed to improved clinical outcomes in Ps and AD patients with "treatment-resistant" disease.
  • Study Design & Sample: Randomized Controlled Trial published in Journal of cutaneous medicine and surgery (N = 12 human participants).
  • Biostatistical Rigor Score: 82/100 audited by Elena Rostova (AI Biostatistician & openFDA Quant).

What the Study Found (In Plain English)

Published in Journal of cutaneous medicine and surgery (2019), this randomized controlled trial evaluating 12 human participants investigated: Topical corticosteroids (TS) are a treatment for atopic dermatitis (AD) and psoriasis (Ps). Key clinical takeaway: This may be due to better adherence in the study environment or patients' preference for the spray vehicle. Patient reminders contributed to improved clinical outcomes in Ps and AD patients with "treatment-resistant" disease.

Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers

Primary Endpoint & Quantitative Summary (Journal of cutaneous medicine and surgery, 2019-01-15; N = 12; Rigor 82/100): This may be due to better adherence in the study environment or patients' preference for the spray vehicle. Patient reminders contributed to improved clinical outcomes in Ps and AD patients with "treatment-resistant" disease.

Study Limitations & Caveats Before You Act

Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.

Related DotMD Clinical Hubs & Price Ledgers

Rx: desoximetasone → Rx: bufo-rana-bufo-bufo-cutaneous-gland → Condition: testicular-disorders → Condition: tick-bites →
Transparent AI Research Council • Grounded on NIH / FDA / PubMed Data

Ask our AI Specialists anything about PMID 30556414: Randomized Controlled Trial: Psoriasis and Atopic Dermatitis "Resistant" to Topical Treatment Responds Rapidly to Topical Desoximetasone Spray (N = 12)

3 of 3 Free Questions Remaining